Back to research

Research paper

EMA 2026 guidelines: clinical investigation of medicinal products in the treatment of epileptic disorders (update)

EMA 2026 updated clinical trial design guidelines for investigational antiepileptic medicinal products. Includes specific considerations for pediatric DEE populations with small patient numbers, biomarker endpoints (EEG/SWI) alongside seizure frequency, adaptive trial design, and basket trials across mechanistically related DEEs.

Indexed context

European Medicines Agency

emaregulatoryclinical-trialsepilepsy-guidelinesdees2026

Markdown path

content/research/papers/2026-ema-epilepsy-guidelines-update.md

Findings

EMA 2026 updated clinical trial design guidelines for investigational antiepileptic medicinal products. Includes specific considerations for pediatric DEE populations with small patient numbers, biomarker endpoints (EEG/SWI) alongside seizure frequency, adaptive trial design, and basket trials across mechanistically related DEEs.

Why it may matter for Levi

Regulatory backdrop against which emerging therapies (rapalogs, fenfluramine for DEE-SWAS, CBD, stiripentol) will move from investigational to standard. Supports advocacy framing: EU regulators have formally acknowledged pediatric DEE trial design needs adaptation. Worth revisiting when considering international trial enrollment if a mosaic diagnosis opens a targeted-therapy path.

Paper text

EMA (2026) — Clinical investigation of medicinal products for epileptic disorders (guideline update)

Source

  • European Medicines Agency, 2026 update.

Why in corpus

Cited in the 2026 Manus AI DEE-SWAS review as the regulatory framework shaping how new therapies for DEEs — including DEE-SWAS — can enter clinical trials and eventually reach patients. Relevant for understanding what investigational therapies (rapalogs, fenfluramine for DEE-SWAS, novel ASMs) might realistically become accessible in the near term.

Key findings

  • Updated clinical trial design requirements for investigational antiepileptic medicinal products, including specific considerations for:
    • Pediatric DEE populations with small patient numbers.
    • Acceptance of biomarker endpoints (EEG quantification, SWI) alongside seizure-frequency endpoints.
    • Adaptive trial design and basket trials across mechanistically related DEEs.
  • Recognizes the need for regulatory pathways that accommodate rare-disease and mosaic-disease populations where traditional randomized controlled trials may be infeasible.

Levi-relevant takeaways

  • Not directly actionable for Levi's day-to-day care, but provides the regulatory backdrop against which emerging therapies (rapalogs, fenfluramine in DEE-SWAS, CBD, stiripentol) will move from investigational to standard.
  • Supports advocacy framing: EU regulators have formally acknowledged that pediatric DEE trial design needs to be adapted — this is a tailwind for trials Levi might eventually qualify for.
  • Worth revisiting when considering international trial enrollment options if a mosaic diagnosis opens a targeted-therapy path.